Search results
Added:
6 months ago
Source:
Radcliffe CVRM
Late-breaking results from the pivotal Phase III FINE-ONE study show that finerenone significantly reduces the urine albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D).² The findings, presented at the American Society of Nephrology’s Kidney Week 2025, mark the first positive Phase III results for a new therapy in this high-risk…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
Cardiovascular inflammation is a key driver of atherosclerotic disease, particularly among high-risk patients with chronic kidney disease (CKD). The Ziltivekimab Cardiovascular Outcomes Trial (ZEUS) has been designed to determine if targeting the interleukin-6 (IL-6) signalling pathway with ziltivekimab can improve outcomes in this population.¹ZEUS (NCT05021835) is a multinational, double-blind,…
View more
Added:
6 months ago
Source:
Radcliffe CVRM
While obesity is a known risk factor for premature cardiovascular ageing, the specific impact of body fat distribution has been less clear. A new study analysing data from the UK Biobank suggests that where fat is stored has a significant, and sometimes sex-specific, influence on the biological age of the cardiovascular system.¹This cross-sectional study analysed data from 21,241 participants in…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
For patients with heterozygous familial hypercholesterolemia (HeFH), achieving adequate low-density lipoprotein cholesterol (LDL-C) lowering remains a significant challenge. New results from the BROOKLYN trial suggest that the investigational agent obicetrapib could be an effective add-on therapy for this high-risk population.¹Mechanism of ActionObicetrapib is a highly selective cholesteryl ester…
View more
Added:
1 month ago
Source:
Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc secondary analysis of the SOUL trial has found that once-daily oral semaglutide is associated with early and sustained improvements in multiple cardiovascular (CV) risk factors in high-risk patients with type 2 diabetes (T2D).¹ These findings help to explain the mechanisms behind the primary trial results, which showed a 14% reduction in major adverse…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
A large-scale meta-analysis provides further evidence supporting the use of early changes in albuminuria as a surrogate endpoint for kidney failure in clinical trials for chronic kidney disease (CKD).¹˒² The findings suggest that a reduction in urinary albumin:creatinine ratio (UACR) is strongly associated with a lower risk of long-term adverse kidney outcomes.This individual participant data…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
Written by Mirjam Boros, Radcliffe CardiologyThe optimal dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in high-risk patients with diabetes and multivessel disease remains a key clinical question. The TUXEDO-2 trial aimed to address this by directly comparing the efficacy and safety of ticagrelor versus prasugrel in this specific patient population…
View more
Added:
1 year ago
Source:
Radcliffe CVRM
AUTHOR: Sean DelaneyAmerican Heart Association, 16 Nov, 2024 –Outcomes from theBPROAD (National Key R&D ProgramofChina; NCT03808311) trial revealed that lowering high systolic blood pressure (SBP) with an intensive treatment strategy in patients with type 2 diabetes reduced the risk of major cardiovascular disease as opposed to a standard treatment strategy.Just under 13,000 patients across China…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: David RamseyAmerican Diabetes Scientific Sessions, 23 June 2024 – The data from three studies investigating glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonists in patients with obesity was recently presented at a late-breaking session at the American Diabetes Association’s 84th Scientific Sessions in Orlando…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Jordan Rance; Special Editor: Greg GuilloryAmerican Heart Association, 18 November 2024 – Dr Daniel Judge announced the findings from the ATTRibute-CM OLE study (Eidos Therapeutics; NCT03860935), an open-label extension of the Phase 3 ATTRibute-CM trial. The study aims to evaluate the long-term efficacy and safety of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM)…
View more